Makers of infant formula use misleading marketing and aggressive lobbying tactics to drive sales in a $55 billion-a-year industry, according to a three-paper series from the World Health Organization.
Manufacturers make unsubstantiated claims about their products, such as that they are very similar to actual breast milk, say the WHO papers published Tuesday in The Lancet medical journal calling for an industry crackdown. New products, such as hypoallergenic or organic formulas, are also sometimes marketed with the implication that they have special benefits and are sold at premium prices, the authors said.
The US infant formula supply has been scrutinized since a recall by Abbott Laboratories that was linked to contaminated products led to a nationwide shortage. Yet concerns about the global industry’s outreach, particularly in developing countries, goes back to the late 1970s, when women were discouraged from breastfeeding their children, the WHO says, denying them key health benefits needed in childhood. That problem remains despite public-health efforts to get more women to breastfeed, according to the Lancet series.
“The formula milk industry uses poor science to suggest, with little supporting evidence, that their products are solutions to common infant health and developmental challenges,” said Linda Richter, a developmental psychologist at the University of the Witwatersrand in South Africa. The technique violates the WHO’s 1981 International Code of Marketing of Breast-Milk Substitutes, which advises against free samples and sets standards for labeling, said Richter, who helped write the reports, in a statement.
